Biointron Insights: Antibody Industry Report (Q4 2024 Insights, Trends & Analysis)

Biointron’s Q4 2024 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2024 (October, November, December). This quarter, 6 novel antibody drugs have been approved by at least one regulatory agency around the world: three monoclonal antibodies, two bispecific antibodies, and one antibody-drug conjugate (ADC).

1. Ongericimab (Junshida)

2. Marstacimab (Hympavzi)

3. Zanidatamab (Zilhera)

4. Sacituzumab tirumotecan (佳泰莱; Sac-TMT)

5. Zenocutuzumab (Bizengri)

6. Cosibelimab (Unloxcyt)

Q4 2024 saw several large collaborations and acquisitions of up to USD$1.9 billion in value. Investment in antibody drug startups focused on novel antibody platforms changing glycans, structure, and the use of artificial intelligence.

Gain exclusive insights into current trends such as:

• 📣 6 novel antibody drugs approved for the first time in Q4

• 💸 Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$1.9B

• 📈 A focus on novel platforms from startups with millions in seed funding

• 🤖 Exciting uses for AI in antibody discovery

• 💊 A list of antibody drugs in regulatory review to keep an eye out for in Q1 2025